Gan & Lee Pharmaceuticals. (SHA:603087)
China flag China · Delayed Price · Currency is CNY
67.68
-0.63 (-0.92%)
Oct 28, 2026, 11:29 AM CST

SHA:603087 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
4,3624,0403,0342,5961,7103,612
Other Revenue
12.1512.1511.411.62.40.11
4,3744,0523,0452,6081,7123,612
Revenue Growth
13.69%33.06%16.77%52.31%-52.60%7.44%
Cost of Revenue
1,106985.47777.15724.7443.93399.9
Gross Profit
3,2683,0672,2681,8831,2683,212
Selling, General & Admin
1,5761,6191,4231,1631,3341,302
Research & Development
702.14646.97541.05501.02562.47474.59
Other Operating Expenses
51.7438.529.8323.6120.3726.21
Operating Expenses
2,3302,3071,9741,7031,9441,822
Operating Income
937.76759.74294.58180.03-675.681,390
Interest Expense
-0.11-0.23-0.29-0.55-0.78-0.96
Interest & Investment Income
336.22375.92153.46141.01186.63321.99
Currency Exchange Gain (Loss)
-11.41-11.416.612.4-2.39-0.71
Other Non Operating Income (Expenses)
-113.78-13.51-2.03-0.8-1.6-3.34
EBT Excluding Unusual Items
1,1491,111452.32322.09-493.821,707
Gain (Loss) on Sale of Investments
29.9573.82156.61-17.92-80.66-54.45
Gain (Loss) on Sale of Assets
2.492.651.15-0.49-5.18-1.7
Asset Writedown
-36.93-29.61-5.02-12.55-40.92-
Other Unusual Items
136.0572.4325.3215.0138.144.96
Pretax Income
1,2801,230630.39306.14-582.471,696
Income Tax Expense
97.3786.2215.72-34.09-142.96243.26
Earnings From Continuing Operations
1,1831,144614.66340.23-439.521,453
Minority Interest in Earnings
0.45-0-0.1600
Net Income
1,1831,144614.66340.07-439.521,453
Net Income to Common
1,1831,144614.66340.07-439.521,453
Net Income Growth
27.82%86.05%80.75%--18.04%
Shares Outstanding (Basic)
592593591567563561
Shares Outstanding (Diluted)
592593591567563561
Shares Change
0.58%0.26%4.28%0.58%0.46%5.28%
EPS (Basic)
2.001.931.040.60-0.782.59
EPS (Diluted)
2.001.931.040.60-0.782.59
EPS Growth
27.08%85.58%73.33%--12.12%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-364.73-141.8196.51-443.61-686.76386.09
Free Cash Flow Per Share
-0.62-0.240.16-0.78-1.220.69
Dividend Per Share
1.0001.0001.5000.200-0.300
Dividend Growth
0%-33.33%650.00%---25.00%
Gross Margin
74.71%75.68%74.48%72.21%74.07%88.93%
Operating Margin
21.44%18.75%9.67%6.90%-39.46%38.49%
Profit Margin
27.05%28.22%20.18%13.04%-25.67%40.22%
Free Cash Flow Margin
-8.34%-3.50%3.17%-17.01%-40.11%10.69%
EBITDA
1,2661,057550.61400.79-479.871,571
EBITDA Margin
28.93%26.08%18.08%15.37%-28.03%43.49%
D&A For EBITDA
327.85297.07256.03220.75195.81180.64
EBIT
937.76759.74294.58180.03-675.681,390
EBIT Margin
21.44%18.75%9.67%6.90%-39.46%38.49%
Effective Tax Rate
7.61%7.01%2.49%--14.34%
Revenue as Reported
1,0054,0523,0452,6081,7123,612